1. Home
  2. THCH vs VERU Comparison

THCH vs VERU Comparison

Compare THCH & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TH International Limited Ordinary shares

THCH

TH International Limited Ordinary shares

HOLD

Current Price

$1.74

Market Cap

57.5M

Sector

Finance

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.35

Market Cap

48.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THCH
VERU
Founded
2018
1971
Country
China
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.5M
48.2M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
THCH
VERU
Price
$1.74
$2.35
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
6.7K
340.9K
Earning Date
04-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.24
$0.36
52 Week High
$3.25
$7.33

Technical Indicators

Market Signals
Indicator
THCH
VERU
Relative Strength Index (RSI) 47.87 38.29
Support Level $1.74 $2.11
Resistance Level $1.99 $2.60
Average True Range (ATR) 0.13 0.23
MACD 0.02 -0.09
Stochastic Oscillator 52.82 5.56

Price Performance

Historical Comparison
THCH
VERU

About THCH TH International Limited Ordinary shares

TH International Ltd is the exclusive master franchisee in China for Tim Hortons, a world-wide coffee and bakery shop brand. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under a single reportable segment, Tim Hortons. The company's revenue is derived from sales of food, beverages, and packaged products by company-owned and operated stores, franchise fees, and revenue from other franchise support activities. Its geographic revenue is derived from operations in the PRC.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: